{
    "2018-10-23": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Pfizer-Lilly non-opioid drug helps reduce osteoarthritis pain",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Lilly",
                        "non-opioid",
                        "drug",
                        "reduce",
                        "osteoarthritis",
                        "pain"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients",
                "features": {
                    "keywords": [
                        "Tanezumab",
                        "Phase 3",
                        "Study",
                        "Significant Improvement",
                        "Pain",
                        "Function",
                        "Osteoarthritis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "This IBD Stock Of The Day Is Heading For Fourth Quarter Of Profitability",
                "features": {
                    "keywords": [
                        "IBD",
                        "Stock Of The Day",
                        "Profitability"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Notable ETF Inflow Detected - XLV, LLY, BMY, CVS",
                "features": {
                    "keywords": [
                        "ETF",
                        "Inflow",
                        "XLV",
                        "LLY",
                        "BMY",
                        "CVS"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "How Is Novartis Valued?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Valued"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Eli Lilly",
                        "report"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Investor Expectations to Drive Momentum within Navios Maritime Partners LP, Alliance Data, Eli Lilly, CONVERGEONE HLD, Atkore International Group, and NantKwest â€” Discovering Underlying Factors of Influence",
                "features": {
                    "keywords": [
                        "Investor Expectations",
                        "Momentum",
                        "Navios Maritime",
                        "Alliance Data",
                        "Eli Lilly",
                        "CONVERGEONE HLD",
                        "Atkore International Group",
                        "NantKwest"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "shipping",
                        "data services",
                        "pharmaceuticals",
                        "technology",
                        "industrial goods",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Why Nektar Therapeutics Crashed 17.2% Today",
                "features": {
                    "keywords": [
                        "Nektar Therapeutics",
                        "Crashed",
                        "17.2%",
                        "Today"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}